you're confusing the shareprice and a company's value. a market is neither right nor wrong. that's anthroporphism and is ridiculous in this context - a decimated spec bouncing.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%